Clinical Trial: IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07032662) titled 'IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)' on June 11.

Brief Summary: This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.

Study Start Date: March 18

Study Type: INTERVENTIONAL

Condition: Chronic Inflammatory Demyelinating Polyneuropathy

Intervention: DRUG: IMVT-1402

Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)

DRUG: Placebo

Matching placebo SC QW for 24 weeks (Period 1)

Recruitment Status: RECRUITING

Sponsor: Immunovant Sciences GmbH

Published by HT Digital Content Services with perm...